Optimi Health already supplies MDMA and psilocybin to patients through regulated channels while trading at a valuation that suggests the market barely recognizes its operating business

Optimi Health is presented as a psychedelic company that is already generating real-world activity by supplying MDMA and psilocybin through legal, patient-facing pathways, while its market valuation remains far below what that operating status might imply. The focus is on the gap between commercial execution and investor attention. The underlying subject centers on regulated production, distribution, and access rather than speculative drug development alone. MDMA and psilocybin are framed as substances already moving through compliant channels to actual patients, which distinguishes the company from many publicly traded psychedelic firms that are still pre-revenue or focused mainly on future clinical milestones. That positioning matters because it ties the psychedelic sector to current healthcare delivery, revenue potential, and public-market mispricing. The core claim is that existing sales, regulatory progress, and real patient use could make the company materially undervalued relative to peers and to the broader narrative around psychedelic medicine.